Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Research Professionals

Neither a doctor nor a teaching hospital

Research payments

$4,521,726

548 payments

Through program year 2025, Clinical Research Professionals is reported as receiving $4,521,726 in research payments, across 548 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,629,947 153
2024 Research $1,908,318 120
2023 Research $103,530 22
2022 Research $86,314 37
2021 Research $92,446 135
2020 Research $544,905 54
2019 Research $156,267 27

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $3,027,009 104 payments
  2. Ironwood Pharmaceuticals, Inc $397,752 36 payments
  3. Braintree Laboratories, Inc. $150,608 50 payments
  4. Sage Therapeutics, Inc. $135,331 3 payments
  5. Celgene Corporation $130,379 6 payments
  6. Pfizer Inc. $123,775 95 payments
  7. ACADIA Pharmaceuticals Inc $116,237 12 payments
  8. Avanir Pharmaceuticals, Inc. $108,982 36 payments
  9. AstraZeneca Pharmaceuticals LP $88,513 6 payments
  10. Novo Nordisk AS $60,121 132 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $1,376,149 10 payments
  2. A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis $758,281 57 payments
  3. A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age $740,365 30 payments
  4. C3718-301 $397,752 36 payments
  5. A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Mrna-1403, A Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults 18 Years of Age $152,213 7 payments
  6. A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis $150,608 50 payments
  7. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Sage-718 in Participants With Mild Cognitive Impairment Or Mild Dementia Due to Alzheimer's Disease $135,331 3 payments
  8. Acp-103-045 $116,237 12 payments
  9. 17-Avp-786-205 $108,982 36 payments
  10. A Phase 3 Multicenter Parallelgroup Openlabel Study to Evaluate the Safety Tolerability and Immunogenicity of Respiratory Syncytial Virus Prefusion F Subunit Vaccine When Coadministered With Herpes Zoster Subunit Vaccine in Adults 50 Years of Age $74,135 12 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record